Topics

Horizon’s Phase 3 Trial Evaluating Teprotumumab in Active Thyroid Eye Disease Met Primary and All Secondary Endpoints

14:20 EST 28 Feb 2019 | Speciality Pharma Journal

DUBLIN–(BUSINESS WIRE)–Horizon Pharma plc (Nasdaq: HZNP) today announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED). The study met its primary endpoint, showing more patients treated with teprotumumab compared with placebo had a meaningful improvement in proptosis, or bulging of the eye: 82.9 percent …

Original Article: Horizon’s Phase 3 Trial Evaluating Teprotumumab in Active Thyroid Eye Disease Met Primary and All Secondary Endpoints

NEXT ARTICLE

More From BioPortfolio on "Horizon’s Phase 3 Trial Evaluating Teprotumumab in Active Thyroid Eye Disease Met Primary and All Secondary Endpoints"

Quick Search

Relevant Topic

Thyroid Disorders
The thyroid is a butterfly-shaped gland in the neck, just above thecollarbone and is an endocrine gland that make hormones. These Thyroid hormones control the rate of many activities in the body, including how fast the body burns calories and how fast th...